A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation
2024

Human Antibody Neutralizing SARS-CoV-2 Omicron Variants

Sample size: 474 publication 10 minutes Evidence: high

Author Information

Author(s): Saskia C. Stein, Guido Hansen, George Ssebyatika, Luisa J. Ströh, Okechukwu Ochulor, Elisabeth Herold, Britta Schwarzloh, Doris Mutschall, Jasmin Zischke, Anne K. Cordes, Talia Schneider, Imke Hinrichs, Rainer Blasczyk, Hannah Kleine-Weber, Markus Hoffmann, Florian Klein, Franziska K. Kaiser, Mariana Gonzalez-Hernandez, Federico Armando, Malgorzata Ciurkiewicz, Georg Beythien, Stefan Pöhlmann, Wolfgang Baumgärtner, Albert Osterhaus, Thomas F. Schulz, Thomas Krey

Primary Institution: Hannover Medical School

Hypothesis

Can a human monoclonal antibody effectively neutralize a broad range of SARS-CoV-2 variants, including Omicron?

Conclusion

The identified antibody, pT1616, effectively neutralizes most SARS-CoV-2 variants, including several Omicron subvariants, and protects against severe lung pathology in hamsters.

Supporting Evidence

  • The antibody pT1616 showed strong neutralizing activity against most tested SARS-CoV-2 variants.
  • It effectively reduced viral load in the lungs of infected hamsters.
  • pT1616 binds to a conserved epitope on the SARS-CoV-2 receptor-binding domain.
  • The study highlights the importance of targeting specific epitopes for effective neutralization.
  • pT1616 demonstrated a higher tolerance for mutations compared to other antibodies.
  • The findings suggest potential for pT1616 in therapeutic applications against COVID-19.
  • Structural analysis revealed unique binding characteristics of pT1616.
  • Broad neutralization profiles of antibodies like pT1616 are crucial for pandemic preparedness.

Takeaway

Scientists found a special antibody that can fight off many versions of the COVID-19 virus, helping to keep people safe from getting very sick.

Methodology

The study involved screening sera from patients for neutralizing antibodies, isolating memory B cells, and testing the neutralizing activity of selected antibodies against various SARS-CoV-2 variants.

Potential Biases

Potential bias in selecting sera from patients who may have had varying immune responses.

Limitations

The study primarily focused on a single antibody and its effectiveness against specific variants, which may not represent all possible variants.

Participant Demographics

Patients suffering or recovering from SARS-CoV-2 infection.

Statistical Information

P-Value

p<0.05

Confidence Interval

95%

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1128/jvi.01223-24

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication